Development, Statistical Optimization and Characterization of Fluvastatin Loaded Solid Lipid Nanoparticles: A 3²...

Area of Science:

• Pharmaceutical Nanotechnology
• Drug Delivery Systems
• Bioavailability Enhancement

Background:

• Fluvastatin exhibits low bioavailability (30%) due to poor solubility and extensive first-pass metabolism.
• Short elimination half-life and low oral bioavailability necessitate advanced drug delivery strategies for fluvastatin.
• Solid lipid nanoparticles (SLNs) offer a promising platform for improving the delivery of poorly soluble drugs.

Purpose of the Study:

• To design, optimize, and evaluate fluvastatin-loaded solid lipid nanoparticles (FLV-SLNPs).
• To enhance the bioavailability of fluvastatin through nano-encapsulation.
• To utilize a 3^2 factorial design for efficient formulation optimization.

Main Methods:

• FLV-SLNPs were prepared using the nano-emulsion technique.
• A 3^2 full factorial design was employed, varying lipid and surfactant concentrations.
• Formulations were characterized using XRD, FTIR, DSC, and pharmacokinetic studies in rats.

Main Results:

• Factorial design successfully optimized FLV-SLNPs, with no drug-excipient interactions observed.
• Characterization confirmed the compatibility of fluvastatin with selected formulation components.
• Pharmacokinetic studies showed significantly improved AUC and MRT for FLV-SLNPs compared to pure fluvastatin.

Conclusions:

• Solid lipid nanoparticles provide an effective strategy for enhancing fluvastatin bioavailability.
• Experimental factorial design enables efficient development and optimization of FLV-SLNPs.
• This research validates SLNPs as a viable delivery system for improving the therapeutic efficacy of fluvastatin.